CN106806361B - 二芳基庚烷类化合物的用途 - Google Patents
二芳基庚烷类化合物的用途 Download PDFInfo
- Publication number
- CN106806361B CN106806361B CN201611230519.4A CN201611230519A CN106806361B CN 106806361 B CN106806361 B CN 106806361B CN 201611230519 A CN201611230519 A CN 201611230519A CN 106806361 B CN106806361 B CN 106806361B
- Authority
- CN
- China
- Prior art keywords
- compound
- nmr
- cdcl
- compounds
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 51
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 15
- 206010040047 Sepsis Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 15
- -1 diaryl heptane compounds Chemical class 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 6
- 239000002158 endotoxin Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 22
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 208000013223 septicemia Diseases 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 239000003112 inhibitor Substances 0.000 abstract description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 102
- 239000011734 sodium Substances 0.000 description 37
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 26
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 25
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 229940125878 compound 36 Drugs 0.000 description 16
- 239000012230 colorless oil Substances 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 15
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 15
- 239000007787 solid Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 7
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 7
- 229940126086 compound 21 Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241001533904 Curcuma comosa Species 0.000 description 4
- 235000010180 Curcuma comosa Nutrition 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- WBKMMUGBIOVPMR-IBGZPJMESA-N (2s)-2-(3,4-dimethoxyphenyl)-8,8-dimethyl-2,3-dihydropyrano[2,3-f]chromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1OC2=C3C=CC(C)(C)OC3=CC=C2C(=O)C1 WBKMMUGBIOVPMR-IBGZPJMESA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- DVBKHJCVEISPEN-SFHVURJKSA-N C1=CC=C(C=C1)CC[C@H](CCCCC2=CC=C(C=C2)O)O Chemical compound C1=CC=C(C=C1)CC[C@H](CCCCC2=CC=C(C=C2)O)O DVBKHJCVEISPEN-SFHVURJKSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002035 hexane extract Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- PSWDQTMAUUQILQ-UHFFFAOYSA-N 2-[(6-methoxy-4-methylquinazolin-2-yl)amino]-5,6-dimethyl-1h-pyrimidin-4-one Chemical compound N1=C(C)C2=CC(OC)=CC=C2N=C1NC1=NC(=O)C(C)=C(C)N1 PSWDQTMAUUQILQ-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- QXDWRXCXHXYLNC-UHFFFAOYSA-N 4-phenylheptan-4-ylbenzene Chemical class C=1C=CC=CC=1C(CCC)(CCC)C1=CC=CC=C1 QXDWRXCXHXYLNC-UHFFFAOYSA-N 0.000 description 1
- REDHQYGMUMUFSR-UHFFFAOYSA-N 5-[7-(2,5-dimethoxyphenyl)-3-hydroxyheptyl]-2-methoxyphenol Chemical compound OC=1C=C(C=CC=1OC)CCC(CCCCC1=C(C=CC(=C1)OC)OC)O REDHQYGMUMUFSR-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- KTXCDCXOGYKLHF-UHFFFAOYSA-N C1=CC=C(C=C1)CCCCC(CCC2=CC(=C(C=C2)O)O)O Chemical compound C1=CC=C(C=C1)CCCCC(CCC2=CC(=C(C=C2)O)O)O KTXCDCXOGYKLHF-UHFFFAOYSA-N 0.000 description 1
- OCDMHIAKZSVLCN-UHFFFAOYSA-N CC(=O)OC1=C(C=C(C=C1)CCC(=O)CCCCC2=CC=CC=C2)OC(=O)C Chemical compound CC(=O)OC1=C(C=C(C=C1)CCC(=O)CCCCC2=CC=CC=C2)OC(=O)C OCDMHIAKZSVLCN-UHFFFAOYSA-N 0.000 description 1
- VOSQGNDCGZTSGS-UHFFFAOYSA-N CC(=O)OC1=C(C=C(C=C1)CCC(CCCCC2=CC=CC=C2)O)OC(=O)C Chemical compound CC(=O)OC1=C(C=C(C=C1)CCC(CCCCC2=CC=CC=C2)O)OC(=O)C VOSQGNDCGZTSGS-UHFFFAOYSA-N 0.000 description 1
- ONTKJJHFOWPHNJ-UHFFFAOYSA-N CC(=O)OC1=C(C=C(C=C1)CCC(CCCCC2=CC=CC=C2)OC(=O)C)OC(=O)C Chemical compound CC(=O)OC1=C(C=C(C=C1)CCC(CCCCC2=CC=CC=C2)OC(=O)C)OC(=O)C ONTKJJHFOWPHNJ-UHFFFAOYSA-N 0.000 description 1
- GFPNLXGVDPLBAZ-NTEUORMPSA-N CCC(C(C/C=C/C1=CC=CC=C1)OCC2=CC=CC=C2)O Chemical compound CCC(C(C/C=C/C1=CC=CC=C1)OCC2=CC=CC=C2)O GFPNLXGVDPLBAZ-NTEUORMPSA-N 0.000 description 1
- WWPKMIMZBRWNGM-UHFFFAOYSA-N CCC(CCC=CC=CC(C=CCCC(CC)O)=O)O Chemical compound CCC(CCC=CC=CC(C=CCCC(CC)O)=O)O WWPKMIMZBRWNGM-UHFFFAOYSA-N 0.000 description 1
- LPLCCDCPCXZZMW-UHFFFAOYSA-N COC1=C(C=C(C=C1)CCC(=O)CCCCC2=CC(=CC=C2)O)O Chemical compound COC1=C(C=C(C=C1)CCC(=O)CCCCC2=CC(=CC=C2)O)O LPLCCDCPCXZZMW-UHFFFAOYSA-N 0.000 description 1
- OCNFEWGFIVVJLE-WEVVVXLNSA-N COC1=C(C=CC(=C1)CCC(=O)CC/C=C/C2=CC=CC=C2)O Chemical compound COC1=C(C=CC(=C1)CCC(=O)CC/C=C/C2=CC=CC=C2)O OCNFEWGFIVVJLE-WEVVVXLNSA-N 0.000 description 1
- AHAPAHBSGZUHLC-QKYXPGDISA-N COC1=C(C=CC(=C1)CC[C@@H](CC/C=C/C2=CC=CC=C2)O)O Chemical compound COC1=C(C=CC(=C1)CC[C@@H](CC/C=C/C2=CC=CC=C2)O)O AHAPAHBSGZUHLC-QKYXPGDISA-N 0.000 description 1
- SEHZGAVHRKMPDA-UHFFFAOYSA-N COC1=CC(=C(C=C1)C=CC=CC(=O)C=CC2=CC(=C(C=C2)OC)O)OC Chemical compound COC1=CC(=C(C=C1)C=CC=CC(=O)C=CC2=CC(=C(C=C2)OC)O)OC SEHZGAVHRKMPDA-UHFFFAOYSA-N 0.000 description 1
- VKPPKVUGEKMIKD-UHFFFAOYSA-N COC1=CC(=C(C=C1)C=CC=CC(=O)C=CC2=CC(=CC=C2)O)OC Chemical compound COC1=CC(=C(C=C1)C=CC=CC(=O)C=CC2=CC(=CC=C2)O)OC VKPPKVUGEKMIKD-UHFFFAOYSA-N 0.000 description 1
- BKWQGMMLVCJYDO-UHFFFAOYSA-N COC1=CC(=C(C=C1)CCCCC(=O)CCC2=CC(=C(C=C2)OC)O)OC Chemical compound COC1=CC(=C(C=C1)CCCCC(=O)CCC2=CC(=C(C=C2)OC)O)OC BKWQGMMLVCJYDO-UHFFFAOYSA-N 0.000 description 1
- KAYQLNNXMUNNSK-UHFFFAOYSA-N COC1=CC(=C(C=C1)CCCCC(=O)CCC2=CC(=CC=C2)O)OC Chemical compound COC1=CC(=C(C=C1)CCCCC(=O)CCC2=CC(=CC=C2)O)OC KAYQLNNXMUNNSK-UHFFFAOYSA-N 0.000 description 1
- OUKNVHZQVRJXNP-UHFFFAOYSA-N COC1=CC(=C(C=C1)CCCCC(CCC2=CC(=C(C=C2)OC)O)O)OC Chemical compound COC1=CC(=C(C=C1)CCCCC(CCC2=CC(=C(C=C2)OC)O)O)OC OUKNVHZQVRJXNP-UHFFFAOYSA-N 0.000 description 1
- GQYGSNOQSYKTSE-UHFFFAOYSA-N COC1=CC(=C(C=C1)CCCCC(CCC2=CC(=CC=C2)O)O)OC Chemical compound COC1=CC(=C(C=C1)CCCCC(CCC2=CC(=CC=C2)O)O)OC GQYGSNOQSYKTSE-UHFFFAOYSA-N 0.000 description 1
- UDHBCMFDMSLAIH-UHFFFAOYSA-N COC1=CC(=C(C=C1)OC)C=CC=CC(=O)C=CC2=CC(=C(C=C2)OC)O Chemical compound COC1=CC(=C(C=C1)OC)C=CC=CC(=O)C=CC2=CC(=C(C=C2)OC)O UDHBCMFDMSLAIH-UHFFFAOYSA-N 0.000 description 1
- HREITOYYBLLDCX-UHFFFAOYSA-N COC1=CC(=C(C=C1)OC)CCCCC(=O)CCC2=CC(=C(C=C2)OC)O Chemical compound COC1=CC(=C(C=C1)OC)CCCCC(=O)CCC2=CC(=C(C=C2)OC)O HREITOYYBLLDCX-UHFFFAOYSA-N 0.000 description 1
- JNKIJIABHNAZGY-UHFFFAOYSA-N COC1=CC=C(C=C1)CCC(=O)CCCCC2=CC(=CC=C2)O Chemical compound COC1=CC=C(C=C1)CCC(=O)CCCCC2=CC(=CC=C2)O JNKIJIABHNAZGY-UHFFFAOYSA-N 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 229910017912 NH2OH Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- ZTWALEDNTBGZIQ-UHFFFAOYSA-N O=C1C=CC(=O)C2=CC(CCC3C4(C)CCC(O4)C3(C)C)=CC=C21 Chemical compound O=C1C=CC(=O)C2=CC(CCC3C4(C)CCC(O4)C3(C)C)=CC=C21 ZTWALEDNTBGZIQ-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000234314 Zingiber Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- YOYAICNPBRPHON-UXBLZVDNSA-N [2-acetyloxy-4-[(E)-3-hydroxy-7-phenylhept-6-enyl]phenyl] acetate Chemical compound CC(=O)OC1=C(C=C(C=C1)CCC(CC/C=C/C2=CC=CC=C2)O)OC(=O)C YOYAICNPBRPHON-UXBLZVDNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000012996 alamarblue reagent Substances 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 229960001124 trientine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一类二芳基庚烷类化合物在制备一氧化氮生成抑制剂、治疗炎症、治疗败血症和/或治疗阿尔茨海默病的药物中的用途。试验证明，本发明的化合物可以有效抑制一氧化氮生成、治疗炎症、治疗败血症和治疗阿尔茨海默病，大幅扩展了二芳基庚烷类化合物应用范围，极具临床应用前景。
Description
技术领域
本发明涉及二芳基庚烷类化合物的新用途，具体涉及它们在制备一氧化氮生成抑制剂、治疗炎症、治疗败血症和/或治疗阿尔茨海默病的药物中的用途。
背景技术
二芳基庚烷类化合物是一类具有1、7-二取代芳基并以庚烷骨架为母体结构的化合物的统称。根据其成环与否以及两个苯环连接方式的不同，分为3种类型，即直线型、大环联苯型和环二苯醚型。该类化合物主要存在于植物的根、茎、皮、花以及果皮等部位。由于其独特的化学结构和广泛的药理活性尤其是抗癌活性，近年受到国内外植物化学和药学研究者的普遍关注。已有研究报道，姜属植物中的线性二芳基庚烷类化合物姜黄素，具有较强的抗癌活性以及癌化学预防作用。
体内的NO由一氧化氮合酶(Nitric oxide synthases，NOS)催化L-精氨酸(L-Arg)产生。已知的NOS有不同基因编码的3种同工酶，即神经型(nNOS)、内皮型(eNOS) 和诱导型(iNOS)。诱导型NO合酶iNOS可被一些外来刺激激活，如内毒素(LPS)、干扰素类、细菌、病毒及促炎症因子(TNF-α、IL-1、IL-6)等。NO在体内发挥双重作用，是免疫系统发挥作用不可缺少的调节因子。然而，NO的过度产生则会导致组织损伤，例如导致肝损伤或者炎症等等。
炎症(inflammation)是一种常见的疾病，可以由细菌、病毒感染，组织器官病理变化，免疫系统的异常或者有害物质刺激及物理损伤时引起。
败血症(septicemia)是指致病细菌侵入血液循环中生长繁殖引起的急性全身性感染，临床症状为寒战、高热、皮疹、关节痛及肝脾肿大，部分患者还可出现烦躁、四肢厥冷及紫绀、脉细速、呼吸加快、血压下降等。病死率可达30～50％，尤其是老人、儿童、有慢性病或免疫功能低下者、治疗不及时及有并发症者，预后更为恶劣。
阿兹海默病(Alzheimer's disease，AD)是发生在老年期及老年前期的一种原发性退行性脑病，指的是一种持续性高级神经功能活动障碍，即在没有意识障碍的状态下，记忆、思维、分析判断、视空间辨认、情绪等方面的障碍。其特征性病理变化为大脑皮层萎缩，并伴有β-淀粉样蛋白沉积，神经原纤维缠结，大量记忆性神经元数目减少，以及老年斑的形成。阿兹海默病病因复杂，其发生为多种因素相互作用的结果。目前尚无特效治疗或逆转疾病进展的治疗药物。
发明内容
为解决上述问题，本发明提供了式(Ⅰ)和/或式(Ⅱ)所示二芳基庚烷类化合物在制备一氧化氮生成抑制剂、治疗炎症、治疗败血症和/或治疗阿尔茨海默病的药物中的用途，
其中，R1～R4分别独立地表示无或者苯环上的1～5个取代基，所述取代基分别独立地选自羟基或C1～C4的烷氧基。
进一步地，R3、R4表示苯环上的1个取代基。
进一步地，所述C1～C4的烷氧基为甲氧基。
进一步地，所述式(Ⅰ)、式(Ⅱ)或式(Ⅲ)化合物为如下化合物之一：
进一步地，所述一氧化氮生成抑制剂是抑制巨噬细胞生成一氧化氮和/或抑制巨噬细胞增殖的药物。
进一步地，所述治疗炎症的药物是抑制巨噬细胞生成一氧化氮和/或抑制巨噬细胞增殖的药物。
进一步地，所述治疗败血症的药物是治疗由脂多糖引起的败血症的药物。
进一步地，它是以前述的化合物、或它们的组合、或其药学上可接受的盐、或其溶剂合物为活性成分，加上药学上可接受的辅料制备而成的制剂。
本发明还提供了一种治疗败血症的药物组合物，它是以前述的化合物、或它们的组合、或其药学上可接受的盐、或其溶剂合物为活性成分，加上药学上可接受的辅料制备而成的制剂。
本发明还提供了一种治疗阿尔茨海默病的药物组合物，它是以前述的化合物、或它们的组合、或其药学上可接受的盐、或其溶剂合物为活性成分，加上药学上可接受的辅料制备而成的制剂。
本发明中，所述一氧化氮生成抑制剂指的是对生物体中一氧化氮生成具有抑制作用的药物。
本发明中，C1～C4的烷氧基是指C1、C2、C3、C4的烷氧基，即具有1～4个碳原子的直链或支链的烷氧基。
在本发明的含义之内，“治疗”也包括复发性(relapse)预防或阶段性(phase)预防，以及急性或慢性体征、症状和/或功能失常的治疗。治疗可以是对症治疗，例如抑制症状。它可以在短期内实现，在中期内调整，或者可以说是长期治疗，例如在维持疗法里面。所述预防包括延迟和/或阻止病症、疾病或病况和/或其伴发症状的发作；防止对象染上病症、疾病或病况；或降低对象染上病症、疾病或病况的风险的方法。
试验证明，本发明的化合物可以有效抑制一氧化氮生成、治疗炎症、治疗败血症和治疗阿尔茨海默病，大幅扩展了二芳基庚烷类化合物应用范围，极具临床应用前景。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1为化合物1-37,39-49对LPS诱导RAW264.7巨噬细胞生成NO的影响。C(Curcumin)和D(Dexamethasone)为阳性药物。LPS，0.5μg/mL；Curcumin，5μM；Dexamethasone，10μM。
图2为化合物21、25、34-36抑制LPS诱导RAW264.7巨噬细胞生成NO的IC50值。
图3为化合物对巨噬细胞增殖的抑制作用。
具体实施方式
本发明化合物可以从生物资源获得或者通过有机合成获得。
实施例1二芳基庚烷类化合物的提取、分离和鉴定
1.1仪器设备及材料
Perkin-Elmer FT-IR红外分光光度计，KBr压片；核磁共振实验采用BrukerAVANCE 400核磁共振仪；使用ES-TOFMS和ES-MS质谱分别使用Bruker microTOF and aFinnigan LC-Q II mass spectrometer；旋光测定采用JASCO-1020polarimeter；高效液相色谱：Agilent 1260HPLC，制备柱使用Kromasil 100-10-C18；Merck硅胶60(细于0.063 毫米)和Pharmacia公司交联葡聚糖LH-20。
Curcuma comosa根茎在泰国的Nakhon Pathom Sakon Nakhon和Prachin Buri，凭证标本(Apichart Suksamrarn，052号和074)存放在Faculty of Science,RamkhamhaengUniversity。
1.2化合物分离提取
C.comosa的根茎被切片，风干，研磨并用正己烷和EtOH依次浸渍，然后分别进行减压蒸馏，得到正己烷和EtOH提取物。正己烷和EtOH萃取物通过柱层析(Merck硅胶 60PF254)分级分离，使用正己烷，正己烷-EtOAc，乙酸乙酯，乙酸乙酯-甲醇和甲醇的梯度洗脱。最终，5个新的二苯庚烷类化合物1-5和16个已知的二苯庚烷类化合物 6-21[1,2]。
1.3部分化合物波谱数据
1-(4-Hydroxy-3-methoxyphenyl)-7-phenyl-(6E)-6-hepten-3-one(化合物1)
无色油状物；IR:νmax:3426,2923,2845,1711,1597,1514,1453,1373,1267,1233,1208,1026,967, 811,748,699；1H NMR(400MHz,CDCl3):δ2.82(dd,7.32,7.36,H1),2.70(dd,7.36,7.03,H2),2.55 (dd,8.15,7.72,H4),2.45(dd,7.72,7.26,H5),6.14(dt,7.26,15.8,H6),6.55(d,15.8,H7),6.65(s,H2′), 6.79(d,8.0,H5′),6.64(d,8.0,H6′),7.18-7.28(m,H2″),7.18-7.28(m,H3″),7.17(m,H4″),7.18-7.28 (m,H5″),7.18-7.28(m,H6″),3.82(s,OMe3″)；13C NMR(100MHz,CDCl3):δ29.4(C1),44.7(C2), 209.2(C3),37.0(C4),29.2(C5),128.7(C6),130.7(C7),132.9(C1′),111.1(C2′),146.3(C3′),143.7 (C4′),114.2(C5′),120.9(C6′),137.3(C1″),125.9(C2″),128.4(C3″),127.0(C4″),128.4(C5″),125.9 (C6″),55.8(OMe3′).
(3S)-and(3R)-1-(4-Hydroxy-3-methoxyphenyl)-7-phenyl-(6E)-6-hepten-3-ol(化合物2)
无色油状物；[α]D27.1＝-1.59[EtOH,C＝0.65w/v]；IR:νmax:3359,3193,2923,2852,1659,1630,1515, 1466,1426,1373,1272,1233,1152,1035,965,816,794,735,693；1H NMR(400MHz,CDCl3):δ2.54, 2.66(m,H1),1.70(m,H2),3.63(m,H3),1.59(m,H4),2.26(m,H5),6.15(dt,6.8,15.8,H6),6.33 (d,15.8,H7),6.63(s,H2′),6.75(d,6.4,H5′),6.62(d,6.4,H6′),7.18-7.28(m,H2″),7.18-7.28(m,H3″), 7.12(t,7.0,H4″),7.18-7.28(m,H5″),7.18-7.28(m,H6″),3.78(s,OMe3)；13C NMR(100MHz, CDCl3):δ31.7(C1),39.4(C2),70.9(C3),37.0(C4),29.2(C5),130.2(C6),130.3(C7),133.9(C1′), 120.8(C2′),146.4(C3′),143.7(C4′),114.2(C5′),110.9(C6′),137.5(C1″),125.9(C2″),128.4(C3″),126.9(C4″),128.4(C5″),125.9(C6″),55.8(OMe3′).
2:1Mixture of(3S)-and(3R)-1-(4-Hydroxy-3-methoxyphenyl)-7-phenyl-(4E,6E)-4,6- heptadien-3-ol(化合物3)
淡黄色油状物；
IR:νmax:3398,3025,2933,2858,1613,1600,1515,1463, 1451,1369,1270,1234,1153,1123,1033,991,749,693；1H NMR(400MHz,CDCl3):δ2.65(m,H1), 1.88(m,H2),4.21(m,H3),5.83(dd,6.8,15.1,H4),6.38(dd,10.7,15.1,H5),6.76(dd,10.7,15.6,H6), 6.54(d,15.6,H7),6.70(brs,H2′),6.82(brd,7.4,H5′),6.69(brd,7.4,H6′),7.38(brd,7.2,H2″),7.30 (brt,7.6,H3″),7.24(m,H4″),7.30(brt,7.6,H5″),7.38(brd,7.2,H6″),3.86(brs,OMe3)；13C NMR (100MHz,CDCl3):δ31.3(C1),39.0(C2),72.0(C3),136.2(C4),130.9(C5),128.1(C6),132.8(C7), 133.7(C1′),111.0(C2′),146.4(C3′),143.7(C4′),114.2(C5′),120.9(C6′),137.1(C1″),126.3(C2″),128.6(C3″),127.5(C4″),128.5(C5″),126.3(C6″),55.8(OMe3).
(3S)-1-Phenyl-7-(4-hydroxyphenyl)heptan-3-ol(化合物4)
无色油状物；[α]D 28＝+1.63[EtOH,C＝0.58w/v]；IR:νmax:3297,3025,2930,2856,1598,1513,1495, 1453,1366,1228,1170,1028,824,745,697；1H NMR(400MHz,CDCl3):δ2.56,2.70(m,H1),1.67 (m,H2),3.52(H3),1.41(m,H4),1.29,1.41(m,H5),1.50(m,H6),2.44(t,7.56,H7),7.08-7.15(m, H2′),7.18-7.24(m,H3′),7.08-7.15(m,H4′),7.18-7.24(m,H5′),7.08-7.15(m,H6′),6.92(d,8.30,H2″), 6.66(d,8.30,H3″),6.66(d,8.30,H5″),6.92(d,8.30,H6″)；13C NMR(100MHz,CDCl3):δ31.9(C1), 38.8(C2),71.1(C3),37.2(C4),25.0(C5),31.6(C6),34.8(C7),142.2(C1′),128.3(C2′),125.6(C3′), 128.3(C4′),125.6(C5′),128.3(C6′),133.8(C1″),129.2(C2″),115.0(C3″),154.2(C4″),115.0(C5″),129.2(C6″).
(3S)-1-(3,4-Dihydroxyphenyl)-7-phenyl-(4E,6E)-4,6-heptadien-3-ol(化合物5)
白色固体；m.p.105-106℃；
IR:νmax:3396,3233,3022,2949,2924, 2849,1612,1596,1515,1447,1254,1228,1175,1096,1044,990,825,748,692,513；1H NMR(400 MHz,CDCl3):δ2.57(m,H1),1.77(m,H2),4.16(H3),5.19(dd,6.1,15.2,H4),6.41(dd,10.3,15.2, H5),6.89(dd,10.3,15.6,H6),6.56(d,15.6,H7),6.53(brs,H2′),6.70(brd,7.9,H5′),6.72(brd,7.9, H6′),7.44(brd,7.5,H2″),7.30(brd,7.5,H3″),7.20(brt,7.5,H4″),7.30(brd,7.5,H5″),7.44(brd,7.5, H6″),3.85(D,4.3,OH3),7.59(brs,OH3′4′)；13C NMR(100MHz,CDCl3):δ30.85(C1),39.59(C2), 70.65(C3),138.36(C4),129.40(C5),128.90(C6),131.42(C7),134.01(C1′),119.50(C2′),142.89 (C3′),144.81(C4′),115.03(C5′),115.39(C6′),115.39(C1″),137.53(C2″),126.13(C3″),128.49 (C4″),127.19(C5″),128.49(C6″).
1,7-Diphenylhepta-l,3,5-trien(化合物21)
白色固体；mp 76.0-76.5℃；IR(KBr):3009.5-3101.9,2831.9-2925.9,1595.3,1490.6,1452.0,1427.3, 1073.0,1027.7,992.9,742.6,697.3cm-1；1H NMR(300MHz,CDCl3):δ3.45(d,2H,J＝7.1Hz),5.89 (dt,1H,J＝14.8,7.0Hz),6.14-6.34(m,3H),6.51(d,1H,J＝15.6Hz),6.79(m,1H),7.17-7.39(m, 10H,ArH)；MS m/e(intensity):246(65.0,M+),155(100.0),142(30.5),129(18.2),I15(20.7),103 (3.5),91(31.9).
2.1本发明涉及的二芳基庚烷类化合物可以根据以下路线制备
路线1：
备注:a)HCl.NH2OH,DMF,Pyridine
b)H2,Pd-C,EtOH
c)Ac2O,Pyridine
d)PhCH2Br,DMF,K2CO3 e)PCC,CH2Cl2
路线2：
备注:(i)excess acetaldehyde,20％aq NaOH,EtOH,0–10℃；
(ii)MeI,K2CO3,acetone,rt.；(iii)20％aq NaOH,EtOH,0℃–rt；(iv)H2(balloon)/10％Pd-C,EtOH.
如路线1所示，对化合物6，12和20进行结构修饰，可以获得化合物22-25，26-29，30-33。如路线2所示，不饱和trienone类似物34-37分别根据文献[3]中的条件，碱催化条件下醛醇缩合，在20％的NaOH的存在下，使用乙醇作为溶剂，用cinnamaldehydes 2a 和2b取代cinnamones 1a-d。三个新的二芳基庚烷类似物(39和40-41)和前面的合成方法类似。
2.2部分化合物波谱数据
3-Hydroxyoxime-1,7-diphenyl-(6E)-6-heptene(化合物22)
白色固体；m.p.55-56℃；IR:νmax:3240,3026,2924,1711,1656,1599,1495,1447,1333, 966,941,737,691；1H NMR(400MHz,CDCl3):δ2.93(dd,J＝8.3,7.6Hz,2H,H-1),2.63(dd,J＝8.3,7.6Hz,2H,H-2),2.49(m,2H,H-4),2.42,2.75(m,2H,H-5),6.24(m,1H, H-6),6.46(dd,J＝15.3,10.3Hz,1H,H-7),7.23-7.38(m,9H,overlapping signal of H2′,3′,5′, 6′and H2″-6″)；13C NMR(100MHz,CDCl3):δ29.55(C1),33.90(C2),161.6(C3),31.34(C4),27.95(C5),130.8(C6),131.0(C7),114.8(C1′),128.3(C2′,6′),126.2(C3′,5′),126.8 (C4′),140.7(C1″),128.3(C2″,4″,6″),126(C3″,5″)；ESMS:m/z 280.9[M+H]+(100), [2M+Na]+HR-TOFMS(ES+):280.1703[M+H]+calcd for C19H21NO+H,280.1696.
1-(4-Benzyloxy-7-phenyl-(6E)-6-hepten-3-ol(化合物23)
白色固体；m.p.70-71℃；IR:νmax:3305,3028,2939,2868,1607,1583,1509,1453,1380, 1296,1237,1221,1175,1084,1007,963,896,819,737,691；1H NMR(400MHz,CDCl3):δ2.69,2.77(m,2H,H-1),1.81(m,2H,H-2),3.74(m,1H,H-3),1.69(m,2H,H-4),2.37(m, 2H,H-5),6.24(dt,J＝15.8,6.8Hz,1H,H-6),6.45(d,J＝15.8Hz,1H,H-7),7.16(d,J＝8.3 Hz,2H,H-2′,6′),6.94(d,J＝8.3Hz,2H,H-3′,5′),7.24-7.48(m,10H,H-2″-5″and H-2″′-5″′)5.07(s,2H,-CH 2-C6H5)；13C NMR(100MHz,CDCl3):δ31.1(C1),39.2(C2),70.3(C3), 37.0(C4),29.2(C5),130.2(C6,C7),137.2(C1′),129.2(C2′,6′),114.8(C3′,5′),157.0(C4′),134.3(C1″),125.9(C2″,6″),126.9(C4″),127.4(C3″,5″),137.6(C1″′),127.4(C2″′,6″′),127.8 (C4″′),128.5(C3″′,5″′),70.0(-CH2-C6H5)；ESMS:m/z 378.3[M+H]+；HR-TOFMS(ES+):m/z 395.1983[M+Na]+calcd for C26H28O2+Na,m/z 395.1982
1-(4-Acethoxy)-7-phenylheptan-3-one(化合物24)
无色油状物；IR:νmax:3027,2931,2862,1760,1710,1507,1453,1368,1191,1165,1017,910, 747,699；1H NMR(400MHz,CDCl3):δ2.94(t,J＝7.50Hz,2H,H-1),2.77(t,J＝7.50HZ, 2H,H-2),2.47(br t,J＝7.56Hz,2H,H-4),1.67(br s,4H,H-5,6),2.67(br t,J＝6.38Hz,2H, H-7),7.35(d,J＝8.0Hz,2H,H-2′,6′),7.05(d,J＝8.0Hz,2H,H-3′,5′),7.22-7.33(m,5H, H-2″-6″,2.36(s,3H,-CH 3-C＝O)；13C NMR(100MHz,CDCl3):δ29.0(C1),44.1(C2), 209.7(C3),42.8(C4),23.3(C5),30.9(C6),35.6(C7),142.1(C1′),129.2(C2′,6′),121.4 (C3′,5′),148.9(C4′),138.6(C1″),128.2(C2″,6″),125.7(4″),128.3 (C3″,5″)21.0,169.5(-CH3-C＝O)；ESMS:m/z 347.9[M+Na]+；HR-TOFMS(ES+):m/z 347.1637[M+Na]+calcd for C21H24O3+Na,347.1618.
1-(3,4-Diacetoxyphenyl)-7-phenyl-(6E)-6-hepten-3-ol(化合物25)
无色油状物；IR:νmax:3417,3027,2933,2862,1765,1597,1504,1425,1369,1257,1205, 1179,1109,1011,964,898,831,743,693；1H NMR(400MHz,CDCl3):δ2.65,2.77(m,2H,H-1),1.76(m,2H,H-2),3.67(m,2H,H-3),1.63(m,2H,H-4),2.30(m,2H,H-5),6.20(dt,J＝15.8,8.6Hz,1H,H-6),6.39(d,J＝15.8Hz,1H,H-7),7.00(s,2H,H-2′),7.05(s,2H,H-5′,6′), 7.17-7.29(m,5H,H-2″-6″),2.25(s,3H,-CH 3-C＝O)；13C NMR(100MHz,CDCl3):δ31.3(C1),38.7(C2),70.7(C3),37.0(C4),29.2(C5),130.1(C6,7),130.3(C1′),123.1(C2′),140.9 (C3′),137.5(C4′),123.2(C5′),126.5(C6′),130.3(C1″),125.9(C2″,6″),126.9(4″),128.4 (C3″,5″),20.6,168.4(-CH3-C＝O)；ESMS:m/z 405.8[M+Na]+,HR-TOFMS(ES+):m/z 405.1689[M+Na]+calcd for C23H26O5+Na,405.1672.
1-(3,4-Dihydroxyphenyl)-7-phenylheptan-3-ol(化合物26)
无色油状物；IR:νmax:3319,2931,2856,1603,1518,1495,1451,1361,1279,1191,1111, 1058,954,866,811,786,743,697,631；1H NMR(400MHz,CDCl3):δ2.58(m,2H,H-1),1.69(m,2H,H-2),3.60(m,1H,H-3),1.61(m,2H,H-4),1.31,1.47(m,2H,H-5),1.47(m,2H,H-6),2.58(t,J＝7.65Hz,2H,H-7),6.66(s,2H,H-2′,6′),6.74(d,J＝8.0Hz,1H,H-5′),6.59 (d,J＝8.0Hz,1H,H-6′),7.13-7.17,7.20-7.27(m,5H,H-2″-6″)；13C NMR(100MHz,CDCl3): δ31.4(C1),38.9(C2),71.5(C3),31.3(C4),25.2(C5),37.3(C6),35.8(C7),141.6(C1′), 115.3(C2′,6′),143.5(C3′),142.4(C4′),115.4(C5′),120.6(6′),134.9(C1″),128.2(C2″,6″), 125.6(C4″),128.3(C3″,5″)；ESMS:m/z 599.8[2M-H]-HR-TOFMS(ES+):m/z323.1632[M+Na]+calcd for C19H24O3+Na,323.1618.
1-(3,4-Diacetoxyphenyl)-7-phenylheptan-3-ol(化合物27)
无色油状物；IR:νmax:3423,3026,2932,2857,1766,1603,1504,1425,1369,1257,1206, 1180,1109,1011,899,830,746,699；1H NMR(400MHz,CDCl3):δ2.64,2.76(m,2H,H-1), 1.77(m,2H,H-2),3.59(m,1H,H-3),1.62(m,2H,H-4),1.36,1.47(m,2H,H-5),1.47(m,2H, H-6),2.59(t,J＝7.5Hz,2H,H-7),6.99(s,1H,H-2′),7.05(dd,J＝8.2,8.2),2H,H-5′,6′), 7.14-7.16,7.24-7.27(m,5H,H-2″-6″),2.26(s,6H,-CH 3-C＝O)；13C NMR(100MHz,CDCl3):δ31.4(C1),38.9(C2),71.0(C3),31.3(C4),25.2(C5),37.4(C6),35.8(C7),141.0(C1′),123.1(C2′),142.5(C3′),141.8(C4′),123.2(C5′),125.6(6′),140.0(C1″),128.2(C2″,6″),128.2(C4″),128.3(C3″,5″),20.6(-CH3-),168.4(C＝O)；ESMS:m/z 791.0 [2M+Na]+HR-TOFMS(ES+):m/z 407.1847[M+Na]+calcd for C23H28O5+Na,407.1829.
3-Acetoxy-1-(3,4-diacetoxyphenyl)-7-phenylheptane(化合物28)
无色油状物；IR:νmax:2935,2868,1769,1730,1601,1505,1426,1369,1241,1204,1178, 1110,1011,896,831,747,699；1H NMR(400MHz,CDCl3):δ2.65(m,2H,H-1),1.91(m,2H,H-2),4.98(m,1H,H-3),1.66(m,4H,H-4,5),1.40(br s,2H,H-6),2.65(m,2H,H-7),6.99(s,1H,H-2′),7.13(d,J＝8.3Hz,1H,H-5′),7.08(d,J＝8.3Hz,1H,H-6′),7.20-7.25,7.30-7.34(m,5H,H-2″-6″),2.06,2.32(s,9H,-CH 3-C＝O)；13C NMR(100MHz,CDCl3):δ 35.3(C1),35.6(C2),73.5(C3),31.1(C4),24.7(C5),33.8(C6),31.1(C7),140.4(C1′),123.0(C2′),142.3(C3′),141.8(C4′),123.0(C5′),125.6(6′),140.0(C1″),128.1(C2″,6″),126.3 (C4″),128.3(C3″,5″),20.5,21.0,(-CH3),168.2,168.3,170.8(C＝O)；ESMS:m/z449.80 [M+Na]+HR-TOFMS(ES+):m/z 449.1936[M+Na]+calcd for C25H30O6+Na,449.1935
1-(3,4-Diacetoxyphenyl)-7-phenylheptan-3-one(化合物29)
无色油状物；IR:νmax:2934,2868,1767,1710,1602,1505,1425,1369,1257,1204,1178, 1109,1010,899,831,747,699；1H NMR(400MHz,CDCl3):δ2.84(t,J＝7.5Hz,2H,H-1),2.68(t,J＝7.5Hz,2H,H-2),2.36(t,J＝6.0Hz,2H,H-4),1.58(m,2H,H-5),1.55(m,2H, H-6),2.58(t,J＝6.5Hz,1H,H-7),6.97(s,1H,H-2′),7.04(dd,J＝12.0Hz,8.2Hz,2H, H-5′,6′),7.13-7.16,7.24-7.26(m,5H,H-2″-6″),2.25(s,-CH 3-C＝O)；13C NMR(100MHz,CDCl3):δ28.9(C1),43.8(C2),209.4(C3),42.8(C4),23.3(C5),30.9(C6),35.6(C7),140.0(C1′),123.2(C2′,5′),142.1(C3′),141.8(C4′),123.2(C5′),125.7(C6′),140.2(C1″),128.2 (C2″,6″),126.5(4″),128.3(C3″,5″),20.6,168.3(-CH3-C＝O)；ESMS:m/z 405.8[M+Na]+； HR-TOFMS(ES+):m/z 405.1691[M+Na]+calcd for C23H226O5+Na,405.1672
Cinnamaldehyde(or(E)-3-(2,4-Dimethoxyphenyl)acrylaldehyde)).(化合物3c)
淡黄色固体；IR:νmax 2840,2767,1660,1606,1570,1502,1425,1324,1296,1275,1202, 1166,1023,969,921,835,783cm-1；1H NMR(400MHz,CDCl3):δ9.60(d,J＝7.9Hz,1H),7.71(d,J＝15.9Hz,1H),7.46(d,J＝8.6Hz,1H),6.68(dd,J＝15.9,7.9Hz,1H),6.51(dd,J＝ 8.6,2.3Hz,1H),6.44(d,J＝2.3Hz,1H),3.86(s,3H),3.83(s,1H).；13C NMR(100MHz,CDCl3):δ194.6,163.7,159.9,148.4,130.5,126.8,116.2,105.6,98.3,55.53,55.51；ESMS(+ve):m/z 407[2M+Na]+.
Cinnamaldehyde 2d((E)-3-(2,5-Dimethoxyphenyl)acrylaldehyde).(化合物3d)
淡黄色固体；IR:νmax 2921,2839,2810,2738,2712,1668,1610,1493,1424,1224,1134, 1040,1022,973,846,804,711cm-1；1H NMR(400MHz,CDCl3):δ9.67(d,J＝7.8Hz,1H),7.81(d,J＝16.1Hz,1H),7.05(d,J＝3.0Hz,1H),6.96(dd,J＝9.0,3.0Hz,1H),6.87(d,J＝9.0Hz,1H),6.73(dd,J＝16.1,7.8Hz,1H),3.85(s,3H),3.78(s,3H).；13C NMR(100MHz,CDCl3):δ194.3,153.6,152.8,147.7,129.2,123.5,118.5,113.0,112.6,56.1,55.8；ESMS(+ve):m/z 193[M+H]+.
1,7-Bis(3-hydroxyphenyl)-1,4,6-heptatrien-3-one(化合物34).
橙黄色固体；m.p.191-194℃；ESMS(+ve):m/z 607[2M+Na]+；HR-TOFMS(ES–):m/z291.1019[M–H]–(Calcd.for C19H16O3–H,291.1021).
1-(3-Hydroxyphenyl)-7-(3-methoxyphenyl)-1,4,6-heptatrien-3-one(化合物35).
亮黄非晶固体；m.p.120-122℃；ESMS(+ve):m/z 307[M+H]+；HR-TOFMS(ES+):m/z329.1161[M+Na]+(Calcd.for C20H18O3+Na,329.1154).
1-(3-Methoxyphenyl)-7-(3-hydroxyphenyl)-1,4,6-heptatrien-3-one(化合物36).
亮黄非晶固体；m.p.120-121℃；ESMS(+ve):m/z 307[M+H]+；HR-TOFMS(ES+):m/z329.1157[M+Na]+(Calcd.for C20H18O3+Na,329.1154).
(1-(3-Hydroxyphenyl)-7-(2,4-dimethoxyphenyl)-1,4,6-heptatrien-3-one(化合物39).
橙色固体；IR:νmax 3281,2940,2837,1659,1594,1559,1446,1267,1206,1088,1024,996, 976,860,828,779,672cm-1；1H NMR(400MHz,acetone-d6):δ8.61(s,1H),7.53-7.65(m, 3H),7.16-7.34(m,5H),7.06(dd,J＝15.6,11.2Hz,1H),6.90(m,1H),6.54-6.64(m,3H),3.91 (s,3H),3.84(s,3H)；13C NMR(100MHz,acetone-d6):δ188.8,163.1,160.0,158.7,145.4, 142.5,137.6,137.3,130.8,129.5,128.8,126.2,126.1,120.7,118.9,118.2,115.5,106.8,99.1, 56.0,55.8.；ESMS(+ve):m/z 359[M+Na]+；HR-TOFMS(ES+):m/z359.1250[M+Na]+ (Calcd.for C21H20O4+Na,359.1254).
1-(3-Hydroxy-4-methoxyphenyl)-7-(2,4-dimethoxyphenyl)-1,4,6-heptatrien-3-one(化合物 40).
橙色固体；IR:νmax 3298,3005,2938,2838,1639,1571,1505,1438,1261,1199,1022,984, 836cm-1；1H NMR(400MHz,CDCl3):δ7.57(d,J＝15.8Hz,1H),7.51(dd,J＝15.2,11.2 Hz,1H),7.44(d,J＝8.6Hz,1H),7.25(d,J＝15.6Hz,1H),7.20(d,J＝1.5Hz,1H),7.08(dd, J＝8.3,1.5Hz,1H),6.91(dd,J＝15.6,11.2Hz,1H),6.89(d,J＝15.8Hz,1H),6.84(d,J＝8.3 Hz,1H),6.50(d,J＝15.2Hz,1H),6.49(dd,J＝8.6,2.0Hz,1H),6.43(d,J＝2.0Hz,1H),5.68 (s,1H),3.91(s,3H),3.85(s,3H),3.81(s,3H)；13C NMR(100MHz,CDCl3):δ189.0,161.9, 158.9,148.6,145.9,144.8,142.3,136.8,128.7(2C),127.7,125.4,123.8,122.3,118.4,113.0, 110.6,105.3,98.5,56.0,55.5,55.4；ESMS(-ve):m/z 356[M-H]-；HR-TOFMS(ES+):m/z 389.1367[M+Na]+(Calcd.for C22H22O5+Na,389.1365)
(1-(3-Hydroxy-4-methoxyphenyl)-7-(2,5-dimethoxyphenyl)-1,4,6-heptatrien-3-one(化合物41).
黄色固体；IR:νmax 3228,3001,2945,2839,1635,1630,1557,1505,1233,1133,1016,874, 803cm-1；1H NMR(400MHz,CDCl3):δ7.58(d,J＝15.8Hz,1H),7.51(dd,J＝15.2,11.1Hz, 1H),7.30(d,J＝15.6Hz,1H),7.20(d,J＝1.8Hz,1H),7.08(dd,J＝8.2,1.8Hz,1H),7.05(d, J＝2.2Hz,1H),6.96(dd,J＝15.6,11.1Hz,1H),6.88(d,J＝15.8Hz,1H),6.84(d,J＝8.2Hz, 1H),6.82(overlapped,1H),6.81(overlapped,1H),6.56(d,J＝15.2Hz,1H),5.73(br s,1H), 3.91(s,3H),3.82(s,3H),3.79(s,3H)；13C NMR(100MHz,CDCl3):δ189.0,153.6,152.1, 148.7,145.9,143.9,142.7,136.3,128.9,128.5,127.7,125.8,123.6,122.4,115.7,113.1,112.4, 112.1,110.6,56.2,56.0,55.8；ESMS(+ve):m/z 367[M+H]+；HR-TOFMS(ES+):m/z 389.1365[M+Na]+(Calcd.for C22H22O5+Na,389.1365)
1-(4-Methoxyphenyl)-7-(3-hydroxyphenyl)-heptan-3-one(化合物42).
无色油状物；IR:νmax 3384,2931,2859,1698,1511,1454,1242,1177,1154,1033,825,781, 695cm-1；1H NMR(400MHz,CDCl3):δ7.10(distorted t,J＝8.5Hz,1H),7.07(d,J＝8.5Hz, 2H),6.80(d,J＝8.5Hz,2H),6.69(distorted d,J＝7.5Hz,1H),6.63(distortedd,J＝8.1Hz, 1H),6.56(br s,1H),3.77(s,3H),2.81(distorted t,J＝7.4Hz,2H),2.66(distorted t,J＝7.4 Hz,2H),2.50(distorted t,J＝7.1Hz,2H),2.36(distorted t,J＝6.8Hz,2H),1.44-1.69(m,4H)；13C NMR(100MHz,CDCl3):δ211.0,158.0,155.8,144.0,133.1,129.4,129.3(2C),120.6, 115.3,113.9(2C),112.7,55.3,44.5,42.9,35.5,30.6,28.9,23.3；ESMS(-ve):m/z 311[M-H]-.
1-(3-Hydroxy-4-methoxyphenyl)-7-(3-hydroxyphenyl)-heptan-3-one(化合物43).
无色油状物；IR:νmax 3465,3326,2917,2853,1693,1594,1514,1446,1377,1275,1237, 1198,1131,1025,999,924,780,691cm-1；1H NMR(400MHz,CDCl3):δ7.10(t,J＝7.7Hz, 1H),6.57-6.77(m,6H),3.83(s,3H),2.77(distorted t,J＝7.1Hz,2H),2.65(distorted t,J＝7.0 Hz,2H),2.50(distorted t,J＝6.7Hz,2H),2.36(distorted t,J＝6.5Hz,2H),1.44-1.63(m,4H)；13C NMR(100MHz,CDCl3):δ211.0,155.8,145.4,144.9,144.0,134.3,129.4,120.7,119.8, 115.3,114.5,112.8,110.8,56.0,44.2,42.8,35.4,30.5,29.2,23.3；ESMS(-ve):m/z 327 [M-H]-.
1-(3-Hydroxyphenyl)-7-(2,4-dimethoxyphenyl)-heptan-3-one(化合物44).
无色油状物；IR:νmax 3436,2934,2836,1702,1610,1585,1502,1459,1209,1156,1124,1030, 844,778,687cm-1；1H NMR(400MHz,CDCl3):δ7.11(t,J＝7.8Hz,1H),6.97(d,J＝8.1Hz, 1H),6.71(d,J＝7.6Hz,1H),6.59-6.67(m,2H),6.36-6.44(m,2H),5.13(br s,1H),3.77(s, 3H),3.75(s,3H),2.80(distorted t,J＝7.5Hz,2H),2.66(distorted t,J＝7.5Hz,2H),2.50 (distorted t,J＝7.3Hz,2H),2.38(distorted t,J＝7.2Hz,2H),1.43-1.65(m,4H)；13C NMR (100MHz,CDCl3):δ211.1,159.0,158.2,155.9,142.9,129.9,129.6,123.0,120.4,115.2, 113.1,103.9,98.5,55.3,55.2,43.9,43.0,29.6,29.5,29.1,23.6.；ESMS(-ve):m/z 683[2M-H]-.
1-(3-Hydroxyphenyl)-7-(2,4-dimethoxyphenyl)-heptan-3-ol(化合物45).
无色油状物；IR:νmax 3317,2933,2857,1705,1611,1587,1505,1455,1285,1258,1206, 1153,1035,934,832,783,696cm-1；1H NMR(400MHz,CDCl3):δ7.12(t,J＝8.2Hz,1H),6.98(d,J＝8.1Hz,1H),6.74(d,J＝7.5Hz,1H),6.64(m,2H),6.37-6.44(m,2H),3.77(s,3H),3.76(s,3H),3.60(m,1H),2.70(m,1H),2.60(m,1H),2.52(t,J＝7.5Hz,2H),1.70(m,2H),1.27-1.60(m,6H)；13C NMR(100MHz,CDCl3):δ158.9,158.3,155.9,144.0,129.9,129.6,123.4,120.6,115.4,112.8,103.9,98.6,71.5,55.4,55.3,38.6,37.3,31.9,30.0,29.4, 25.3；ESMS(-ve):m/z 687[2M-H]-.
1-(3-Hydroxy-4-methoxyphenyl)-7-(2,4-dimethoxyphenyl)-heptan-3-one(化合物46).
无色油状物；IR:νmax 3429,2935,2841,1707,1612,1587,1505,1270,1206,1153,1125, 1030,832,801,760cm-1；1H NMR(400MHz,CDCl3):δ6.97(d,J＝8.0Hz,1H),6.73(m,2H),6.62(d,J＝8.1Hz,1H),6.39(m,2H),5.56(br s,1H),3.83(s,3H),3.76(s,3H),3.75(s, 3H),2.77(distorted t,J＝7.4Hz,2H),2.65(distorted t,J＝7.5Hz,2H),2.50(distorted t,J＝ 7.3Hz,2H),2.37(distorted t,J＝7.1Hz,2H),1.47-1.60(m,4H)；13CNMR(100MHz, CDCl3):δ210.4,159.0,158.2,145.5,144.9,134.4,129.9,123.0,119.6,114.4,110.7,103.8, 98.5,56.0,55.3,55.2,44.3,42.9,29.6,29.2(2C),23.6；ESMS(+ve):m/z 767.9[2M+Na]+.
1-(3-Hydroxy-4-methoxyphenyl)-7-(2,4-dimethoxyphenyl)-heptan-3-ol(化合物47).
无色油状物；IR:νmax 3428,2932,2856,2835,1611,1587,1505,1454,1438,1271,1205, 1153,1128,957,920.832,802,760,631cm-1；1H NMR(400MHz,CDCl3):δ6.98(d,J＝8.1 Hz,1H),6.76(br s,1H),6.74(distorted d,J＝8.4Hz,1H),6.65(d,J＝8.0Hz,1H),6.41(br s, 1H),6.39(distorted d,J＝8.3Hz,1H),5.55(br s,1H),3.84(s,3H),3.77(s,6H),3.59(m,1H), 2.67(m,1H),2.57(m,1H),2.51(t,J＝7.5Hz,2H),1.69(m,2H),1.26-1.60(m,6H)；13C NMR (100MHz,CDCl3):δ159.0,158.3,145.5,144.7,135.6,129.9,123.4,119.7,114.6,110.7, 103.8,98.5,71.3,56.0,55.3,55.2,39.1,37.4,31.4,30.1,29.4,25.4.；ESMS(+ve):m/z 771.8 [2M+Na]+.
1-(3-Hydroxy-4-methoxyphenyl)-7-(2,5-dimethoxyphenyl)-heptan-3-one(化合物48).
无色油状物；IR:νmax 3406,2932,2835,1589,1497,1440,1272,1218,1128,1044,1025,957, 867,800,760cm-1；1H NMR(400MHz,CDCl3):δ6.60-6.76(m,6H),5.54(br s,1H),3.83(s, 3H),3.74(s,6H),2.77(distorted t,J＝7.5Hz,2H),2.65(distorted t,J＝7.4Hz,2H),2.54 (distorted t,J＝7.3Hz,2H),2.38(distorted t,J＝7.1Hz,2H),1.55(m,4H)；13C NMR(100 MHz,CDCl3):δ210.3,153.4,151.7,145.5,144.9,134.4,131.9,119.6,116.2,114.4,111.2, 110.8,110.7,56.0,55.9,55.6,44.3,42.9,29.9,29.4,29.2,23.6；ESMS(+ve):m/z 767 [2M+Na]+.
1-(3-Hydroxy-4-methoxyphenyl)-7-(2,5-dimethoxyphenyl)-heptan-3-ol(化合物49).
无色油状物；IR:νmax 3406,2932,2857,2835,1589,1497,1440,1272,1218,1128,1044,1025, 957,867,800,760,710cm-1；1H NMR(400MHz,CDCl3):δ6.60-6.79(m,6H),5.56(br s,1H), 3.84(s,3H),3.75(s,3H),3.74(s,3H),3.59(m,1H),2.67(m,1H),2.56(m,3H),1.27-1.80(m, 8H)；13C NMR(100MHz,CDCl3):δ153.4,151.7,145.4,144.7,135.5,132.3,119.6,116.2, 114.6,111.2,110.6(2C),71.2,55.9(2C),55.3,39.0,37.3,31.3,30.1,29.4,25.4；ESMS(+ve): m/z 771[2M+Na]+.
2.3参考文献：
1.Suksamrarn,A.,Ponglikitmongkol,M.,Wongkrajang,K.,Chindaduang,A.,Kittidanairak,S.,Jankam,A.,Yingyongnarongkul,B.,Kittipanumat,N.,Chokchaisiri,R., Khetkam,P.,Piyachaturawat,P.Diarylheptanoids,new phytoestrogens from therhizomes of Curcuma comosa:Isolation,chemical modification and estrogenicactivity evaluation.Bioorg. Med.Chem.2008,16,6891-6902.
2.Sornkaew,N.,Lin,Y.,Wang,F.,Zhang,G.,Chokchaisiri,R.,Zhang,A.,Wongkrajang, K.,Suebsakwong,P.,Piyachaturawat,P.and Suksamrarn,A.Diarylheptanoids of Curcuma comosa with Inhibitory Effects on Nitric OxideProduction in Macrophage RAW 264.7Cells. Natural Product Communications.2015,10(1),89-93.
3.Chuprajob,T.；Changtam,C.；Chokchaisiri,R.；Chunglok,W.；Sornkaew N.；Suksamrarn,A.Synthesis,cytotoxicity against human oral cancer KB cells andstructure-activity relationship studies of trinone analogues ofcurcuminoids.Bioorg.Med.Chem. lett.2014,16,2839-2844.
4.Sodsai,A.；Piyachaturawat,P.；Sophasan,S.；Suksamrarn,A.；Vongsakul,M.Suppression by Curcuma comosa Roxb.of pro-inflammatory cytokine secretion inphorbol-12-myristate-13-acetate stimulated human mononuclearcells.Int.Immunopharmacol. 2007,7,524-531.
实施例2二芳基庚烷类化合物抑制NO产生的活性作用。
1材料
化合物(1-37,39-49)；小鼠RAW264.7巨噬细胞；内毒素(LPS，0.5μg/mL)；BAY (10μM，阳性对照)NO检测试剂盒(Beyotime，Haimen，China)。
2主要仪器
荧光酶标仪(Thermo Scienti fic，Waltham，MA，USA)
3方法
3.1 LPS刺激RAW264.7巨噬细胞生成NO的测定
RAW264.7巨噬细胞接种于96-孔板，每孔接种量为1×104细胞，待接种细胞贴壁以后，加入待测化合物(1-37,39-49)孵育2h，然后加入LPS(终浓度为0.5μg/mL)，继续培养24h。最后取96孔板培养基，用NO试剂盒进行检测，NO的含量通过测定其OD550来表示。每次实验取3个复孔，重复3次实验。
3.2 NO抑制率的计算
NO的抑制率(％)，根据以下公式进行计算：
抑制率(％)＝(A-B)/(A-C)×100，
A：LPS(+)，化合物(－)；B：LPS(+)，化合物(+)，C：LPS(－)，化合物(－)。
3.3统计方法
所有的统计方法均使用GraphPad Prism 5.01软件进行处理。数据以平均数±标准误差表示，数据使用单因素方差分析(ANOVA)。p<0.05
4结果
结果如图1所示，结果表明化合物21，25，34-36在初筛浓度为5μM条件下，可明显抑制LPS诱导的NO生成，其抑制率在80％以上。
进一步测定活性较好的化合物21，25，34-36的IC50值，结果如图2所示，它们的IC50值在0.32-1.61μM。
实施例3二芳基庚烷类化合物对巨噬细胞增殖的抑制作用
1材料
化合物(1-37,39-49)；小鼠RAW264.7巨噬细胞；Alamar-Blue试剂。
2主要仪器
荧光酶标仪(Thermo Scienti fic，Waltham，MA，USA)
3方法
3.1化合物(1-37,39-49)对RAW264.7巨噬细胞增殖的影响
接种RAW264.7巨噬细胞于96-孔板，每孔接种1×104细胞，待接种细胞贴壁以后，加入待测化合物(1-37,39-49)孵育24h。然后每个每孔加入Am-Blue细胞增殖与活性检测试剂(SunBioTM)10μL并于培养箱中孵育2～6小时。当培养基的颜色由靛青蓝变成粉红色后用荧光酶标仪测定各孔相对荧光单位(RFU值)，激发光波长560nm，发射光波长590nm。每次实验取3个复孔，重复3次实验。
3.2统计方法
所有的统计方法均使用GraphPad Prism 5.01软件进行处理。数据以平均数±标准误差表示，数据使用单因素方差分析(ANOVA)，当p<0.05时有统计学意义。
4结果
测定抑制NO生成活性较好的化合物21,25,27-29,34-37,39,41,40的IC50值，结果如图 3所示，化合物34-36在20μM的浓度下对细胞增殖有明显的抑制作用，IC50值19.26-21.12 μM。
实施例4化合物21、化合物34、化合物36抑制LPS诱导的大鼠败血症
1材料
化合物21、化合物34、化合物36；健康SD雄性大鼠，体重260～310g；LPS。
2方法
(1)SD雄性大鼠分成8组(control、LPS、化合物21、化合物34、化合物36)，体重260～310g，每组10只。
(2)用化合物(化合物21、化合物34、化合物36,浓度均为25mg/kg)预处理组于尾静脉予，然后立即腹腔注射LPS(10mg/kg)；LPS模型组尾静脉予以生理盐水后，立即腹腔注射LPS(10mg/kg)；Control组仅尾静脉予以生理盐水。
(3)各组均于4h后予3％戊巴比妥钠(10ml/100g)麻醉，将充满肝素生理盐水的动脉插管插入右颈总动脉描记血压10min，10min后于左颈总动脉取血。
3结果
结果如表1。腹腔大剂量注射LPS后，LPS模型组血小板1min聚集度(PAG1)、5min 聚集度(PAG5)、最大聚集度(MA)、最大聚集时间(TMA)与Control组对比均显著下降；在化合物21、化合物34、化合物36预处理组血小板聚集性各项指标较LPS模型组明显升高。表明化合物21、化合物34、化合物36显著抑制LPS诱导的大鼠败血症。
表1化合物对败血症大鼠血小板聚集性的影响
备注：5min聚集度(PAG1)、5min聚集度(PAG5)、最大聚集度(MA)、最大聚集时间(TMA)；**P<0.01各个化合物组vs LPS组。
实施例5化合物36抑制小鼠老年痴呆(AD)模型
1材料
化合物36健康昆明种小鼠雌雄各半，体重25～30g，随机分为6组，即正常对照组、模型组、化合物36实验组，每组10只。
2方法
2.1动物实验
(1)昆明种小鼠雌雄各半，体重25～30g，随机分为6组，正常对照组、模型组化合物36实验组，每组10只。
(2)模型组及各试验药物组小鼠每天颈背部皮下给予1％D-半乳糖(150mg/kg)注射，共6周，在2周对化合物36实验组进行灌胃给药实验(25mg/kg)，模型组生理盐水处理，共4周。
2.2 Morris水迷宫系列试验
隐蔽平台试验水迷宫为直径100cm，高50cm的圆形水池，水池内壁被漆为黑色，池内水深25cm，水温保持在25度，房间内光照恒定，无光线直射在水池内。池壁上以4 个等距离点将水池分为4个象限，任选其中1个象限，正中放置1个圆形黑色安全平台，直径为12cm，高24cm，位于水面下1cm。迷宫上方安置连接显示系统的摄像机，同步记录大鼠运动轨迹。实验历时5d，每天上下午各1次，入池位置为平台所邻2个象限的池壁中点。将小鼠面向池壁分别从入水点放入水中，记录其在100s内寻找到平台的时间(逃避潜伏期)。如果小鼠在100s未找到平台，则由实验者用手牵引其至平台上，停留10s，逃避潜伏期记成100s。每天以两次潜伏期算术均值作为这一天的成绩进行统计分析。
探索试验撤除平台，任选1个入水点将小鼠放入水中，使小鼠在无平台情况下寻找记忆中平台，记录其100s内的游泳轨迹，计算其在原平台象限游泳时间和穿越原平台次数。
3结果
表2的结果表明，隐蔽平台试验从第1天起，模型组小鼠的逃避潜伏期明显长于正常组；化合物36实验组显著增加痴呆小鼠逃避潜伏期。因此表明在用化合物36后能改善痴呆小鼠的学习记忆能力。
表2各实验组隐蔽平台试验逃避潜伏期比较
备注：**P<0.01各个化合物组VS AD模型组；*P<0.05各个化合物组vs AD模型组。
表3结果表明，观察小鼠的空间探索能力，发现模型组小鼠基本围绕池壁游泳，其运动轨迹呈随机分布于各象限之中；化合物36实验组停留原平台象限时间和穿越原平台次数均明显多于模型组，再次表明化合物36可以提高痴呆小鼠的记忆能力。
表3各实验组小鼠探索试验比较
备注：**P<0.01化合物组VS AD模型组；*P<0.05化合物组vs AD模型组。
综上所述，本发明的化合物可以有效抑制一氧化氮生成、治疗炎症、治疗败血症和治疗阿尔茨海默病，大幅扩展了二芳基庚烷类化合物应用范围，极具临床应用前景。
Claims (3)
1.二芳基庚烷类化合物在制备治疗败血症和/或治疗阿尔茨海默病的药物中的用途，所述二芳基庚烷类化合物选自以下化合物：
2.根据权利要求1所述的用途，其特征在于：所述治疗败血症的药物是治疗由脂多糖引起的败血症的药物。
3.根据权利要求1所述的用途，其特征在于：所述药物是以权利要求1所述的二芳基庚烷类化合物、或它们的组合、或其药学上可接受的盐为活性成分，加上药学上可接受的辅料制备而成的制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611230519.4A CN106806361B (zh) | 2016-12-28 | 2016-12-28 | 二芳基庚烷类化合物的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611230519.4A CN106806361B (zh) | 2016-12-28 | 2016-12-28 | 二芳基庚烷类化合物的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106806361A CN106806361A (zh) | 2017-06-09 |
| CN106806361B true CN106806361B (zh) | 2020-03-06 |
Family
ID=59110336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611230519.4A Active CN106806361B (zh) | 2016-12-28 | 2016-12-28 | 二芳基庚烷类化合物的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106806361B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1884246A (zh) * | 2006-06-29 | 2006-12-27 | 天津大学 | 从高良姜中提取二芳基庚烷类化合物的方法 |
| CN104628501A (zh) * | 2014-11-08 | 2015-05-20 | 吕梁学院 | 一种核桃青皮中二芳基庚烷化合物分离与制备方法 |
-
2016
- 2016-12-28 CN CN201611230519.4A patent/CN106806361B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1884246A (zh) * | 2006-06-29 | 2006-12-27 | 天津大学 | 从高良姜中提取二芳基庚烷类化合物的方法 |
| CN104628501A (zh) * | 2014-11-08 | 2015-05-20 | 吕梁学院 | 一种核桃青皮中二芳基庚烷化合物分离与制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| Diarylheptanoids from the Rhizomes of Curcuma kwangsiensis;Jun Li 等;《J. Nat. Prod.》;20101231;第73卷(第10期);第1667–1671页 * |
| Induction of apoptosis in murine leukemia by diarylheptanoids from Curcuma comosa Roxb.;Surawat Jariyawat 等;《Cell Biol Toxicol》;20111231;第27卷;第413–423页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106806361A (zh) | 2017-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | Quercetin hinders microglial activation to alleviate neurotoxicity via the interplay between NLRP3 inflammasome and mitophagy | |
| Qu et al. | Transcription factor NRF2 as a promising therapeutic target for Alzheimer’s disease | |
| Gabriele et al. | Anti-inflammatory and antioxidant effect of fermented whole wheat on TNFα-stimulated HT-29 and NF-κB signaling pathway activation | |
| Yan et al. | Lingzhilactones from Ganoderma lingzhi ameliorate adriamycin-induced nephropathy in mice | |
| Watanabe et al. | Isolation and characterization of a phenolic antioxidant from the Pacific oyster (Crassostrea gigas) | |
| JP3178806B2 (ja) | ウルシ抽出物を含む抗癌剤組成物 | |
| Yan et al. | Identification and biological evaluation of flavonoids from the fruits of Prunus mume | |
| EP1292319B1 (en) | Extracts from spermatophyte plants with antitumor activity | |
| Gaur et al. | In vitro and in vivo synergistic interaction of substituted chalcone derivatives with norfloxacin against methicillin resistant Staphylococcus aureus | |
| Skaf et al. | Improving anti-trypanosomal activity of alkamides isolated from Achillea fragrantissima | |
| Hao et al. | β-Carboline alkaloids from the deep-sea fungus Trichoderma sp. MCCC 3A01244 as a new type of anti-pulmonary fibrosis agent that inhibits TGF-β/smad signaling pathway | |
| CN106831383A (zh) | 二芳基庚烷类化合物 | |
| Awale et al. | Targeting pancreatic cancer with novel plumbagin derivatives: Design, synthesis, molecular mechanism, in vitro and in vivo evaluation | |
| Tewabe et al. | Antimalarial potential of the leaf exudate of Aloe macrocarpa todaro and its major constituents against plasmodium berghei | |
| CN106806361B (zh) | 二芳基庚烷类化合物的用途 | |
| CN113248525B (zh) | 狗牙花属植物提取物及其提取分离方法和用途 | |
| CN109771428B (zh) | 雷公藤红素联合erastin在治疗非小细胞肺癌的药物中的应用 | |
| KR101250181B1 (ko) | 감수에서 분리된 테르페노이드 또는 이를 포함하는감수추출물을 함유하는 골다공증 예방 및 치료용 약학조성물 | |
| US8927594B2 (en) | Compounds from soft coral, method of preparation and pharmaceutical uses thereof | |
| CN110790639A (zh) | 治疗大肠癌的化合物 | |
| KR102612269B1 (ko) | 떨꿩나무 잎 유래 화합물 및 이를 포함하는 타이로시나제 활성 저해능력 조성물 | |
| Petro-Buelvas et al. | Synthesis and antileishmanial activity of styrylquinoline-type compounds: in vitro and in vivo studies | |
| AU2021106089A4 (en) | Application of lycopene cis isomer in preparing drugs for treating ovarian cancer | |
| Piao et al. | Anti-Toxoplasma gondii agent isolated from Orostachys malacophylla (Pallas) Fischer | |
| CN111939185B (zh) | 一种中草药提取物、提取方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |